Sage Journals: Discover world-class research

Abstract

Background:

Patients with alcohol use disorder (AUD) frequently initiate their recovery by first completing treatment in an inpatient withdrawal management unit, but many are not connected to ongoing care after discharge. We sought to evaluate the correlation between the use of medications for AUD (MAUD) on confirmed linkage to care.

Methods:

We conducted a retrospective review of every patient admitted for alcohol withdrawal management to an American Society of Addiction Medicine Level IV unit for intensive inpatient withdrawal management from September 2021 to November 2022 to evaluate whether initiation or continuation of MAUD was associated with confirmed linkage to ongoing post-discharge addiction treatment. Data were collected via the institution’s electronic health record (EHR). Confirmed linkage was defined as having confirmation in the EHR for attending the planned follow-up appointment within 30 days of discharge. Statistically significant differences in unadjusted analyses were included in a logistic regression model to account for confounders.

Results:

There were 312 unique patient encounters. Fifty-three (17%) had their linkage confirmed, and 127 (40.7%) were discharged on MAUD. Among MAUDs, only extended-release naltrexone (XR-NTX) was associated with a greater likelihood of linkage (28.3% vs 10.8%, P = .001). In adjusted analyses, those receiving XR-NTX (adjusted odds ratio [aOR] 2.7, 95% confidence interval [CI] 1.3-5.6, P = .009) and drinks per drinking day prior to admission (aOR 0.96, 95% CI 0.92-0.99, P = .016) remained significant predictors of linkage to care.

Conclusions:

XR-NTX may enhance post-discharge care linkage. Further research is warranted to examine the potential role of MAUDs in improving AUD-related outcomes after the completion of inpatient treatment.

Keywords

naltrexone acamprosate disulfiram gabapentin topiramate alcohol use disorder alcohol withdrawal continuum of care

Get full access to this article

View all access options for this article.

References

Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS) Discharges. Substance Abuse and Mental Health Services Administration; 2019.

SAMHSA’s working definition of recovery. Patient brochure . Substance Abuse Mental Health Services Administration. Published February 1, 2012. Accessed April 23, 2024. https://store.samhsa.gov/sites/default/files/pep12-recdef.pdf

Lee

Horgan

Garnick

, et al. A performance measure for continuity of care after detoxification: relationship with outcomes. J Subst Abuse Treat. 2014;47(2):130-139.

Roy

Price

Choi

, et al. Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge. Drug Alcohol Depend. 2021;224:108703.

McPheeters

O’Connor

Riley

, et al. Pharmacotherapy for alcohol use disorder a systematic review and meta-analysis. JAMA. 2023;330(17):1653-1665.

D’Onofrio

O’Connor

Pantalon

, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636-1644.

Livingston

Ameral

Hocking

, et al. Interventions to improve post-detoxification treatment engagement and alcohol recovery: systematic review of intervention types and effectiveness. Alcohol Alcohol. 2022;57(1):136-150.

Bernstein

Baggett

Trivedi

, et al. Outcomes after initiation of medications for alcohol use disorder at hospital discharge. JAMA Netw Open. 2024 29;7(3):e243387.

Bernstein

Lebin

Hoppe

, et al. Variation in initiation of medications for alcohol use disorder during alcohol withdrawal hospitalizations in a large health system: a retrospective cohort study. J Hosp Med. Published online October 8, 2025. doi:10.1002/jhm.70201

10.

Hartung

McCarty

, et al. Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies. J Subst Abuse Treat. 2014;47(2):113-121.

11.

Anderson

Chamberlin

Zuluaga

, et al. Implementation of oral and extended-release naltrexone for the treatment of emergency department patients with moderate to severe alcohol use disorder: feasibility and initial outcomes. Ann Emerg Med. 2021;78(6):752-758.

12.

Murphy

IV Coralic

Wang

, et al. Extended-release naltrexone and case management for treatment of alcohol use disorder in the emergency department. Ann Emerg Med. 2023;81(4):440-449.

13.

Magane

Dukes

Fielman

, et al. Oral vs extended-release injectable naltrexone for hospitalized patients with alcohol use disorder: a randomized clinical trial. JAMA Intern Med. 2025;185(6):635-645.

14.

Chutuape

Katz

Stitzer

ML.

Methods for enhancing transition of substance dependent patients from inpatient to outpatient treatment. Drug Alcohol Depend. 2001;61(2):137-143.

15.

O’Farrell

Murphy

Alter

Fals-Stewart

Brief family treatment intervention to promote continuing care among alcohol-dependent patients in inpatient detoxification: a randomized pilot study. J Subst Abuse Treat. 2008;34(3):363-369.

16.

Blondell

Frydrych

Jaanimagi

, et al. A randomized trial of two behavioral interventions to improve outcomes following inpatient detoxification for alcohol dependence. J Addict Dis. 2011;30(2):136-148.

17.

Nielsen

Outreach visits improve referral of alcohol dependent patients from psychiatric hospital to continued care. A randomized trial. Nord J Psychiatry. 2018;72(4):303-310.

18.

Timko

Below

Vittorio

, et al. Randomized controlled trial of enhanced telephone monitoring with detoxification patients: 3- and 6-month outcomes. J Subst Abuse Treat. 2019;99:24-31.

19.

Suzuki

Loguidice

Prostko

, et al. Digitally assisted peer recovery coach to facilitate linkage to outpatient treatment following inpatient alcohol withdrawal treatment: proof-of-concept pilot study. JMIR Form Res. 2023;7:e43304.